Company Overview
Company Type: Public Company
Website: www.questpharmatech.com
Number of Employees: -
Ticker: QPT (TSXV)
Year Founded: -


Business Description
Quest PharmaTech Inc., a pharmaceutical company, engages in the development of novel therapeutics for the treatment of targeted cancer. Its lead product candidate is Mab AR 9.6 against truncated O-glycan on MUC16, for targeted cancer therapy applications. The company also offers Oregovomab, which is in Phase III clinical trial for the treatment of ovarian cancer. In addition, it develops, manufactures, and commercializes immunotherapy products for pancreatic cancer; and combinatorial immunotherapeutic products for the treatment cancer by using monoclonal antibodies of the immunoglobulin of G and E class. Quest PharmaTech Inc. is headquartered in Edmonton, Canada.

Financial Information (Currency: CAD, in mm) 
Market Capitalization
10.1
EBITDA
(1.2)
Total Enterprise Value
11.0
TEV/EBITDA
NM
EBIT
(1.2)
Cash & ST Invst.
0.1
P/Diluted EPS Before Extra
NM
Net Income
(20.7)
Total Debt
1.0
Price/Tang BV
0.1x
Total Assets
69.7
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jul-31-2023 TEV and Market Cap are calculated using a close price as of Oct-04-2023

Key Professionals
Name
Title
Madiyalakan, Ragupathy 
CEO & Director
Vermette, Pierre 
Chief Financial Officer
Andrews, Roger 
Head of Investor Relations & Corporate Communications
Bachman, Douglas C.
Vice President of Corporate Development
Woo, Thomas 
Vice President of Product Development

Key Board Members
Name
Title
Meikle, Lorne T.
Chairman
Madiyalakan, Ragupathy 
CEO & Director
Lievonen, John Mark
Independent Director
Nicodemus, Christopher 
Chairman of Scientific Advisory Board
Beauchamp, Norma 
Director
Hollingsworth, Michael A.
Member of Scientific Advisory Board
Hwang, Ki-Jun 
Member of Scientific Advisory Board
Meekison, William John
Director
Moore, Ronald 
Member of Scientific Advisory Board
Shon, Jeffrey 
Independent Director


Primary Industry Classification
Biotechnology


Primary Office Location
4342 - 97 street NW | Edmonton, AB | T6E 5R9 | Canada

Current and Pending Investors
ADBiotech Co., Ltd. (KOSDAQ:A179530), Hepalink USA Inc., KMH Co., Ltd.

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.06
Market Cap (mm)
10.1
Open
 0.06
Shares Out. (mm)
169.1
Previous Close
 0.06
Float %
82.0%
Change on Day
0.0050
Shares Sold Short (mm)
-
Change % on Day
9.1%
Dividend Yield %
-
Day High/Low
 0.06/ 0.06
Diluted EPS Excl. Extra Items
(0.12)
52 wk High/Low
 0.11/ 0.05
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0070
Avg 3M Dly Vlm (mm)
0.03
Beta 5Y
0.76


 
Delayed Quote** | Last Updated on Oct-04-2023 12:00 AM (GMT-5)


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Paladin Labs Inc., 5 Late-Stage Immunotherapy Product Candidates
As of September 28, 2009, 5 Late-Stage Immunotherapy Product Candidates of Paladin Labs Inc. were acquired by Quest PharmaTech Inc. 5 Late-Stage Immunotherapy Product Candidates of Paladin Labs Inc. comprises five monoclonal antibodies for the treatment of cancer. The products include Oregovomab, an anti-CA125 antibody for the treatment of ovarian cancer; anti-MUC1; anti-TAG72; anti-PSA; and anti-CA19.9 antibodies used for the treatment of breast, lung, stomach, colorectal, pancreas, and prostate cancer. Paladin Labs, Inc. is headquartered in St. Laurent, Canada.

United States and Canada
Pharmaceuticals
-
-
-
Horizon Capital Inc.
As of March 29, 1999, Horizon Capital, Inc. was acquired by Steroidogenesis Inhibitors Canada, Inc. in a reverse merger transaction.

United States and Canada
Asset Management and Custody Banks
0.00
0.00
0.00
Madenco BioSciences, Inc

United States and Canada
-
-
-
-
Natural Rf Life Sciences Inc.
Natural Rf Life Sciences Inc. produces natural health products for seasonal and environmental allergies. Its products are used to get relief from allergy-related nasal discomforts, such as stuffy nose, itchy nose, watery eyes, and itchy eyes; and respiratory symptoms. The company was founded in 2017 and is headquartered in Edmonton, Canada.

United States and Canada
Pharmaceuticals
-
-
-
OncoQuest Inc.
OncoQuest Inc. develops immunotherapeutic products for the treatment of cancer. The company was founded in 2015 and is based in Edmonton, Canada. OncoQuest Inc. operates as a subsidiary of Quest PharmaTech, Inc.

United States and Canada
Pharmaceuticals
-
-
-
SonoLight Pharmaceuticals Corp.

-
-
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Sep-28-2022
Sep-28-2022
Merger/Acquisition
Seller
Bioceltran Co., Ltd

Quest PharmaTech Inc. (TSXV:QPT)
0.22
May-04-2017
Jul-31-2017
Merger/Acquisition
Buyer
Natural Rf Life Sciences Inc.
Quest PharmaTech Inc. (TSXV:QPT)

0.36
Dec-10-2015
Dec-10-2015
Merger/Acquisition
Seller
Quest PharmaTech Inc., Immuno-photodynamic Therapy Assets
OncoQuest Inc.
Quest PharmaTech Inc. (TSXV:QPT)
2.00
Oct-13-2015
Oct-13-2015
Private Placement
Target
Quest PharmaTech Inc. (TSXV:QPT)
Hepalink USA Inc.

1.54
Jul-27-2015
Jul-27-2015
Private Placement
Target
Quest PharmaTech Inc. (TSXV:QPT)


1.00
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jul-13-2023
Annual General Meeting
Quest PharmaTech Inc., Annual General Meeting, Jul 13, 2023
Jul-13-2023
Shareholder/Analyst Calls
Quest PharmaTech Inc. - Shareholder/Analyst Call
Jul-10-2023
Product-Related Announcements
Quest PharmaTech Inc. Provides Product Development Update
May-31-2023
Auditor Going Concern Doubts
Quest PharmaTech Inc. Auditor Raises 'Going Concern' Doubt
Sep-28-2022
M&A Transaction Closings
Sang Ho Jang acquired unknown minority stake in Bioceltran Co., Ltd from Quest PharmaTech Inc. (TSXV:QPT) for CAD 0.3 million.


Advisors
Most Recent Auditor
Kingston Ross Pasnak LLP
Key development Advisor
Loewen Ondaatje McCutcheon Limited, Investment Banking Arm


Most Recent Auditor
Kingston Ross Pasnak LLP


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
ValuEngine, Inc.

Oct 02, 2023 06:36 AM
QPT
ValuEngine - Toronto Quantitative Stock Report for QPT
Reports
5
GlobalData

Sep 15, 2023 04:06 AM
QPT
Quest PharmaTech Inc (QPT.CVE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
19
GlobalData

Sep 13, 2023 03:27 AM
QPT
Quest PharmaTech Inc (QPT.CVE) - Financial Analysis Review
Reports
104
GlobalData

Aug 23, 2023 06:45 AM
QPT
Quest PharmaTech Inc (QPT.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
44
GlobalData

Jun 09, 2023 02:59 AM
QPT
Quest PharmaTech Inc (QPT.CVE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

Jun 09, 2023 02:06 AM
QPT
Quest PharmaTech Inc (QPT.CVE) - Financial Analysis Review
Reports
104
GlobalData

Apr 26, 2023 07:13 AM
QPT
Quest PharmaTech Inc (QPT.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
42
GlobalData

Mar 29, 2023 04:47 AM
QPT
Quest PharmaTech Inc (QPT.CVE) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
42
GlobalData

Mar 10, 2023 05:55 AM
QPT
Quest PharmaTech Inc (QPT.CVE) - Pharmaceuticals and Healthcare Product Pipeline Summary
Reports
17
GlobalData

Mar 09, 2023 12:28 AM
QPT
Quest PharmaTech Inc (QPT.CVE) - Financial Analysis Review
Reports
102


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


Shenzhen Hepalink Pharmaceutical Group Co., Ltd.

25,000,000

14.78

1.4

Jul-13-2023


Madiyalakan Ph.D., Ragupathy 

3,200,000

1.89

0.2

Sep-15-2023


Vermette C.A., CPA, Pierre 

1,830,518

1.08

0.1

Jul-24-2023


Shon J.D., Jeffrey 

350,000

0.21

0.0

Jul-13-2023



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
Madiyalakan Ph.D., Ragupathy 
3,200,000
103,290

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Accu-MAb, ACP 2127, Bionex, CDK Technology, Distribution of Anticort, Distribution of Consumer Health Products, Licensing of Photodynamic Therapy Technology, Licensing of SonoLight Technology, Mab AR 9.6 (Future), SL017 (Future), SL052 (Future), Sonodynamic Therapy (Future), Therapeutic Antibody Platform


Upcoming Events
Date/Time
Type
Dec-21-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Period Date
Company Name
Source
Form Type
Size
Sep-21-2023
Jul-31-2023
Quest PharmaTech Inc. (TSXV:QPT)
SEDAR
Interim Financial Statements
366 KB
Sep-13-2023
-
Quest PharmaTech Inc. (TSXV:QPT)
SEDAR
News Releases
43 KB
Jul-14-2023
-
Quest PharmaTech Inc. (TSXV:QPT)
SEDAR
News Releases
41 KB
Jul-10-2023
-
Quest PharmaTech Inc. (TSXV:QPT)
SEDAR
News Releases
28 KB
Jun-29-2023
Apr-30-2023
Quest PharmaTech Inc. (TSXV:QPT)
SEDAR
Interim Financial Statements
244 KB
Jun-16-2023
-
Quest PharmaTech Inc. (TSXV:QPT)
SEDAR
Management Proxy Materials
72 KB
Jun-16-2023
-
Quest PharmaTech Inc. (TSXV:QPT)
SEDAR
Management Proxy Materials
70 KB
Jun-16-2023
-
Quest PharmaTech Inc. (TSXV:QPT)
SEDAR
Management Proxy Materials
122 KB
Jun-16-2023
-
Quest PharmaTech Inc. (TSXV:QPT)
SEDAR
Management Proxy Materials
379 KB
Jun-09-2023
-
Quest PharmaTech Inc. (TSXV:QPT)
SEDAR
News Releases
31 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Madiyalakan Ph.D., Ragupathy  (CEO & Director)
Sep-15-2023
Common Shares
15,290
1,088
Open Market Acquisition
0.48
Multiple
Madiyalakan Ph.D., Ragupathy  (CEO & Director)
Sep-06-2023
Common Shares
8,000
563
Open Market Acquisition
0.25
Multiple
Madiyalakan Ph.D., Ragupathy  (CEO & Director)
Aug-29-2023
Common Shares
30,000
2,124
Open Market Acquisition
0.95
Multiple
Madiyalakan Ph.D., Ragupathy  (CEO & Director)
Aug-25-2023
Common Shares
20,000
1,412
Open Market Acquisition
0.64
Multiple
Madiyalakan Ph.D., Ragupathy  (CEO & Director)
Aug-22-2023
Common Shares
30,000
2,129
Open Market Acquisition
0.97
Multiple
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Meikle, Lorne T.
Chairman
(416) 868-9310
(416) 868-9140
LorneMeikle@biocatalyst.com
Madiyalakan, Ragupathy 
CEO & Director
(780) 448-1400x204
-
madi@questpharmatech.com
Lievonen, John Mark
Independent Director
-
-

Nicodemus, Christopher 
Chairman of Scientific Advisory Board
-
-

Beauchamp, Norma 
Director
-
-

Hollingsworth, Michael A.
Member of Scientific Advisory Board
-
-

Hwang, Ki-Jun 
Member of Scientific Advisory Board
-
-

Meekison, William John
Director
(604) 649-8778
-
wjmeekison@gmail.com
Moore, Ronald 
Member of Scientific Advisory Board
-
-
-
Shon, Jeffrey 
Independent Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Madiyalakan, Ragupathy 
CEO & Director
(780) 448-1400x204
-
madi@questpharmatech.com
Vermette, Pierre 
Chief Financial Officer
-
(780) 416-0324
pierre@questpharmatech.com
Andrews, Roger 
Head of Investor Relations & Corporate Communications
-
-
-
Bachman, Douglas C.
Vice President of Corporate Development
-
-

Woo, Thomas 
Vice President of Product Development
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
